Choksi laboratories Limited has announced the reconstitution of its key board committees following changes in director composition, effective February 07, 2026. The pharmaceutical company informed BSE Limited about these structural changes in compliance with SEBI listing regulations.

Director Changes Drive Committee Restructuring

The reconstitution became necessary after Mrs. Meenaxi Patidar (DIN: 10206356) ceased to be a Non-Executive Independent Director on January 09, 2026, following her resignation from the position. Her departure resulted in her automatic cessation from all board committees of the company.

To fill the vacancy, the Board of Directors approved the appointment of Mr. Ritik Pavecha (DIN: 08790431) as an additional director in the category of Non-Executive Independent Director during their meeting on February 07, 2026. This appointment remains subject to approval from shareholders.

Reconstituted Committee Compositions

The company has restructured three critical committees to ensure compliance with regulatory requirements under Sections 177 and 178 of the Companies Act, 2013, and SEBI listing regulations.

Audit Committee

Nomination and Remuneration Committee

Stakeholders' Relationship Committee

Regulatory Compliance

The reconstitution ensures adherence to Regulations 18, 19, and 21 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. All three committees now maintain the required composition of independent directors as mandated by regulatory frameworks.

The company secretary and compliance officer, Prakhar Dubey, signed the regulatory filing digitally, confirming the formal communication to BSE Limited regarding these governance changes. The restructured committees became effective immediately from February 07, 2026.

Choksi Laboratories Limited has announced the resignation of Mrs. Meenaxi Patidar from her position as Non-Executive Independent Director, effective January 09, 2026. The resignation was communicated to the Bombay Stock Exchange on January 10, 2026, in compliance with regulatory requirements.

Resignation Details

Mrs. Patidar, who holds Director Identification Number (DIN) 10206356, submitted her resignation via email on January 09, 2026. She cited preoccupation and personal commitments as the primary reasons for stepping down from her directorial role.

Impact on Board Committees

Following her resignation as Independent Director, Mrs. Patidar has also ceased her involvement in key board committees. She was serving as a Member of the Audit Committee and held the position of Chairperson of the Nomination & Remuneration Committee.

The departure creates vacancies in these critical governance committees that will need to be addressed by the company's board of directors in due course.

Regulatory Compliance

Choksi Laboratories Limited has fulfilled all mandatory disclosure requirements under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company provided comprehensive details as required by the SEBI Master Circular dated November 11, 2024.

Director's Confirmation

In her resignation letter addressed to the Board of Directors, Mrs. Patidar expressed gratitude for the trust and support received during her tenure. She specifically confirmed that there are no other material reasons for her resignation beyond the preoccupation and personal commitments mentioned in her letter.

The resignation was processed by Company Secretary and Compliance Officer Prakhar Dubey, who signed the regulatory filing on January 10, 2026. Mrs. Patidar wished the company continued success and prosperity in her farewell message to the board and company members.